Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


‘File Over Protest’ At US FDA: PTC To Pursue Rarely-Used Pathway For DMD Drug

Executive Summary

Translarna’s best path forward is the file over protest pathway for the application, which received a refuse to file letter last year, PTC says; former OND Director John Jenkins calls it ‘a fairly rare event.’


Related Content

Refining A Controversial Endpoint: Sarepta Banking On Dystrophin Levels For Golodirsen Approval In DMD
Keeping Track: Apadaz Approved Without Abuse-Deterrent Label, FDA Denies Translarna Appeal, And Some Priority Reviews
Keeping Track: A Burst of CRLs and BTDs, A Busy Week Of Submissions And Another Approval For Soliris
Keeping Track: Oncology Approvals And Responses To Complete Response Letters
No More Sarepta-Like Development, FDA Officials Say
Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
FDA Finds Fault With Third Duchenne Muscular Dystrophy Drug Filing
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited
Rejected Out of Hand: FDA "Refuse-to-File" Letters Hit Five-Year High


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts